Acino ? Delivering Health

More documents

Recommendations

Info

Entering emerging markets - hurdles to overcome Entry of emerging markets – Highly fragmented regulatory environment > Increased requirements for stability (Zone IVB) > Local bioequivalence / clinical studies required > Trends toward local production > Limited uptake of alternative generic products by authorities Market environment – Market size – Many markets are flooded with cheap commodities (Indian/Chinese/local origin) – Many markets are dispensing markets (low quantities/low turnover) – Patients pay out of their own pocket, decision making done by physician/patient (brand equity) 42
Opportunities Products with added value – Generics + – Products with application/compliance advantages (AOD, patches, implants) – Niche products (few competition) Therapeutic areas – Life threatening and related diseases (cancer, Aids, Malaria) – Life-style products (Sildenafil, herbals) – Upcoming western diseases (obesity, diabetes) – Women healthcare 43
Page 1 and 2: Acino - Delivering Health Investor
Page 3 and 4: Acino - drug delivery specialist, m
Page 5 and 6: Acino’s growth drivers Fully expl
Page 7 and 8: Technology platform Oral modified r
Page 9 and 10: Oral modified release forms MUPS (M
Page 11 and 12: Technology platform Oral dispersibl
Page 13 and 14: Technology platform Transdermal sys
Page 15 and 16: Transdermal systems Why transdermal
Page 17 and 18: Technology platform Extended releas
Page 19 and 20: Extended release parenterals Advant
Page 21 and 22: Development projects Ferrous sulfat
Page 23 and 24: Development projects Rivastigmine T
Page 25 and 26: Development projects Goserelin & le
Page 27 and 28: Development projects Goserelin 1 &
Page 29 and 30: Development projects Leuprorelin 1
Page 31 and 32: Acino’s development pipeline Stat
Page 33 and 34: Acino - Delivering Health Thank you
Page 35 and 36: Entering emerging markets / “Swis
Page 37 and 38: Acino Switzerland 2009 BtC markets
Page 39 and 40: Acino Switzerland 2011 BtC markets
Page 41: Acino Switzerland 2013 BtC markets
Page 45 and 46: Acino Switzerland: Product Portfoli
Page 47 and 48: Acino portfolio Roll-out in new ter
Page 49 and 50: Criteria for selecting products for
Page 51 and 52: Acino’s business model (example)
Page 53 and 54: Optimized BtB Concept - Geographica
Page 55 and 56: Technical Marketing and Operations:
Page 57 and 58: Acino’s production importance Tec
Page 59 and 60: Production Technologies: Value for
Page 61 and 62: Pellets Innovative technologies for
Page 63 and 64: Pellet Projects High volume project
Page 65 and 66: Granulates Hot melt granulation Sp
Page 67 and 68: Manufacturing Process 67
Page 70 and 71: Implants Implant manufacturing capa
Page 72 and 73: Opportunity: High Quality Service S
Page 74 and 75: Summary Focus on niche technologies
Page 76 and 77: Competitive advantage factor: HighT
Page 78 and 79: Micro Error Tracking System (METS)
Page 80 and 81: Strategy to cope with declining mar
Page 82 and 83: Financials Robert Schmid, Head of I
Page 84 and 85: Promising potential areas of synerg
Page 86 and 87: Reduced currency exposure Mepha / C
Page 88 and 89: Summary and strategy Peter Burema,
Page 90 and 91: Acino’s growth drivers Fully expl
Page 92 and 93:
Geographic break-down of revenue DE
Page 94:
Acino - Delivering Health Thank you
show all

Acino ? Delivering Health

Create successful ePaper yourself

Delete template?

Save as template?